MX2019014292A - Anillos 5-5 fusionados como inhibidores c5a. - Google Patents

Anillos 5-5 fusionados como inhibidores c5a.

Info

Publication number
MX2019014292A
MX2019014292A MX2019014292A MX2019014292A MX2019014292A MX 2019014292 A MX2019014292 A MX 2019014292A MX 2019014292 A MX2019014292 A MX 2019014292A MX 2019014292 A MX2019014292 A MX 2019014292A MX 2019014292 A MX2019014292 A MX 2019014292A
Authority
MX
Mexico
Prior art keywords
inhibitors
fused rings
modulators
receptor
diseases
Prior art date
Application number
MX2019014292A
Other languages
English (en)
Inventor
Christopher W Lange
Venkat Reddy Mali
Sreenivas Punna
Rebecca M Lui
Yibin Zeng
Pingchen Fan
Viengkham Malathong
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2019014292A publication Critical patent/MX2019014292A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Abstract

La presente exposición proporciona, inter alia, los Compuestos de la Fórmula (I) (ver fórmula I) o sales farmacéuticamente aceptables de los mismos que son moduladores del receptor C5a. También se proporcionan composiciones farmacéuticas y métodos de uso que incluyen el tratamiento de enfermedades o trastornos que implican la activación patológica de C5a y aplicaciones no farmacéuticas.
MX2019014292A 2017-05-31 2018-05-29 Anillos 5-5 fusionados como inhibidores c5a. MX2019014292A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762513025P 2017-05-31 2017-05-31
PCT/US2018/034908 WO2018222601A1 (en) 2017-05-31 2018-05-29 5-5 FUSED RINGS AS C5a INHIBITORS

Publications (1)

Publication Number Publication Date
MX2019014292A true MX2019014292A (es) 2022-04-07

Family

ID=64455572

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014292A MX2019014292A (es) 2017-05-31 2018-05-29 Anillos 5-5 fusionados como inhibidores c5a.

Country Status (16)

Country Link
US (2) US10683294B2 (es)
EP (1) EP3630774B1 (es)
JP (1) JP7141129B2 (es)
KR (1) KR102586710B1 (es)
CN (1) CN111032658B (es)
AR (1) AR111841A1 (es)
AU (1) AU2018277523B2 (es)
BR (1) BR112019025230A2 (es)
CA (1) CA3064025A1 (es)
ES (1) ES2934507T3 (es)
IL (1) IL270842B2 (es)
MA (1) MA48800A (es)
MX (1) MX2019014292A (es)
TW (1) TWI813570B (es)
WO (1) WO2018222601A1 (es)
ZA (1) ZA201907755B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222598A1 (en) 2017-05-31 2018-12-06 Chemocentryx, Inc. 6-5 FUSED RINGS AS C5a INHIBITORS
WO2018222601A1 (en) 2017-05-31 2018-12-06 Chemocentryx, Inc. 5-5 FUSED RINGS AS C5a INHIBITORS
EP3728203B1 (en) * 2017-12-22 2024-03-13 ChemoCentryx, Inc. DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
CN111788184B (zh) * 2017-12-22 2023-12-22 凯莫森特里克斯股份有限公司 用作C5aR抑制剂的二芳基取代的5,5-稠合环化合物
EP3773563A4 (en) * 2018-04-02 2021-12-29 ChemoCentryx, Inc. Prodrugs of fused-bicyclic c5ar antagonists
EP3996711A4 (en) 2019-07-10 2023-08-16 ChemoCentryx, Inc. INDANES AS PD-L1 INHIBITORS
CN112300169B (zh) * 2019-07-26 2022-03-04 上海美迪西生物医药股份有限公司 吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
CA3192880A1 (en) 2020-10-28 2022-05-05 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ524475A (en) 2000-08-10 2004-11-26 Pharmacia Italia S Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
DE60039921D1 (de) 2000-09-29 2008-09-25 Neurogen Corp Hochaffine kleinmolekülige c5a-rezeptor-modulatoren
SE524438C2 (sv) 2000-10-05 2004-08-10 Magnus Georg Goertz Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium
WO2002088122A1 (fr) 2001-04-26 2002-11-07 Ajinomoto Co., Inc. Composes heterocycliques
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
EP1487798A4 (en) 2002-03-28 2005-07-13 Neurogen Corp Substituted tetrahydroisoquinolines as C5A receptor modulators
EP1487796A4 (en) 2002-03-28 2005-11-16 Neurogen Corp SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR
JP2005530719A (ja) 2002-03-29 2005-10-13 ニューロジェン コーポレーション 病原性炎症要素を有する状態の治療のための組み合わせ療法
AU2003265395A1 (en) 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
AU2003265625A1 (en) 2002-08-21 2004-03-11 Neurogen Corporation Amino methyl imidazoles as c5a receptor modulators
WO2004043925A2 (en) 2002-11-08 2004-05-27 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
US20060154917A1 (en) 2003-07-03 2006-07-13 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
WO2006042102A2 (en) * 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
WO2007051062A2 (en) * 2005-10-28 2007-05-03 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
PE20110063A1 (es) 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
MA32975B1 (fr) 2008-12-22 2012-01-02 Chemocentryx Inc Antagonistes de c5ar
SI2585064T1 (sl) 2010-06-24 2017-08-31 Chemocentryx, Inc. Antagonisti C5AR
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
EP2885304B8 (en) 2012-08-16 2016-12-07 Janssen Pharmaceutica NV Pyrrolopyrazoles as n-type calcium channel blockers
CN103421006B (zh) 2013-08-18 2016-06-22 上海师范大学 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN109310686B (zh) 2016-04-04 2022-06-21 凯莫森特里克斯股份有限公司 可溶性C5aR拮抗剂
WO2018222598A1 (en) 2017-05-31 2018-12-06 Chemocentryx, Inc. 6-5 FUSED RINGS AS C5a INHIBITORS
WO2018222601A1 (en) 2017-05-31 2018-12-06 Chemocentryx, Inc. 5-5 FUSED RINGS AS C5a INHIBITORS
EP3728203B1 (en) 2017-12-22 2024-03-13 ChemoCentryx, Inc. DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
CN111788184B (zh) 2017-12-22 2023-12-22 凯莫森特里克斯股份有限公司 用作C5aR抑制剂的二芳基取代的5,5-稠合环化合物
EP3773563A4 (en) 2018-04-02 2021-12-29 ChemoCentryx, Inc. Prodrugs of fused-bicyclic c5ar antagonists

Also Published As

Publication number Publication date
IL270842B1 (en) 2023-01-01
JP7141129B2 (ja) 2022-09-22
IL270842A (en) 2020-01-30
EP3630774A4 (en) 2020-10-07
TWI813570B (zh) 2023-09-01
RU2019142985A (ru) 2021-06-30
EP3630774A1 (en) 2020-04-08
CN111032658A (zh) 2020-04-17
EP3630774B1 (en) 2022-11-23
AR111841A1 (es) 2019-08-21
WO2018222601A1 (en) 2018-12-06
US20210009594A1 (en) 2021-01-14
AU2018277523A1 (en) 2019-12-05
IL270842B2 (en) 2023-05-01
CN111032658B (zh) 2022-12-20
US10683294B2 (en) 2020-06-16
BR112019025230A2 (pt) 2020-06-16
RU2019142985A3 (es) 2021-09-03
KR20200013720A (ko) 2020-02-07
ZA201907755B (en) 2023-05-31
ES2934507T3 (es) 2023-02-22
AU2018277523B2 (en) 2022-06-23
US20180346471A1 (en) 2018-12-06
US11479553B2 (en) 2022-10-25
JP2020522483A (ja) 2020-07-30
CA3064025A1 (en) 2018-12-06
TW201902897A (zh) 2019-01-16
KR102586710B1 (ko) 2023-10-10
MA48800A (fr) 2020-04-08

Similar Documents

Publication Publication Date Title
ZA201907746B (en) 6-5 fused rings as c5a inhibitors
NZ765590A (en) Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors
MX2020006459A (es) Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
MX2019014292A (es) Anillos 5-5 fusionados como inhibidores c5a.
MX2020010390A (es) Profarmacos de antagonistas de c5ar biciclicos fusionados.
NZ768368A (en) Modulators of cystic fibrosis transmembrane conductance regulator
MX2020001236A (es) Compuestos aza biciclicos como agonistas del receptor muscarinico m1.
MX2018001564A (es) Compuestos farmaceuticos.
NZ737399A (en) Ccr2 modulators
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
MX2019002438A (es) Compuestos triciclicos fusionados de piridazinona utiles para tratar infecciones de orthomyxovirus.
TW201613864A (en) Novel compounds
PH12019500568A1 (en) Dopamine-b-hydroxylase inhibitors
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
PH12018500432A1 (en) Heteroaryl compounds and their use as therapeutic drugs
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
PH12017501668A1 (en) Bace1 inhibitors
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
PH12018501563A1 (en) Indane derivatives as mglur7 modulators
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
JOP20200104A1 (ar) مركبات مثبطة لـ btk
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.
PH12019502792A1 (en) Tetrahydropyridopyrazine modulators of gpr6